Drugs / JV001
JV001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05837143 | Mar 2023 → Jul 2025 overdue | dilated cardiomyopathy, heart failure | Shanghai East Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05837143 ↗ |
| Known as | AAV9-cTnT-modTERT | “The aim of this study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing a modified telomerase protein (TERT), driven by cardiac...” NCT05837143 ↗ |
| Known as | AAV9/modTERT | “JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory.” NCT05837143 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated viral vector expressing a modified telomerase protein (TERT)” NCT05837143 ↗ |
| Route | Other | “single intracoronary infusion of JV001” NCT05837143 ↗ |
| Target | TERT | “an adeno-associated viral vector expressing a modified telomerase protein (TERT)” NCT05837143 ↗ |